BR0212454A - Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto - Google Patents
Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um compostoInfo
- Publication number
- BR0212454A BR0212454A BR0212454-8A BR0212454A BR0212454A BR 0212454 A BR0212454 A BR 0212454A BR 0212454 A BR0212454 A BR 0212454A BR 0212454 A BR0212454 A BR 0212454A
- Authority
- BR
- Brazil
- Prior art keywords
- sup
- compound
- sub
- emesis
- anxiety
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 206010047700 Vomiting Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000036407 pain Effects 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 title 1
- 102000003141 Tachykinin Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 208000004296 neuralgia Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108060008037 tachykinin Proteins 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA O TRATAMENTO OU PREVENçãO DE DISTúRBIOS FISIOLóGICOS ASSOCIADOS COM UM EXCESSO DE TAQUICININAS E DE DOR OU INFLAMAçãO, ENXAQUECA, êMESE, NEURALGIA PóS-TERPéTICA, DEPRESSãO OU ANSIEDADE, E, USO DE UM COMPOSTO". A presente invenção refere-se a compostos de Fórmula (I) em que R^ 1^, R^ 2~, R^ 3^, R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^ e R^ 10^ representam uma variedade de substituintes; A representa NR^ 9^ ou O; B representa uma ligação, CH~ 2~, NR^ 9^ ou O, em que um ou ambos átomos de hidrogênio de dita porção CH~ 2~pode(m) ser substituído(s) por um ou ambos de R^ 7^ e R^ 8^ ou, alternativamente, um dos átomos de hidrogênio de dita porção CH~ 2~, junto com um átomo de hidrogênio de um carbono adjacente, é substituído com uma dupla ligação; com a condição de que, quando A for O, então B seja NR^ 9^; n seja zero, 1 ou 2; e seus sais farmaceuticamente aceitáveis. Os compostos são de particular uso no tratamento ou prevenção da depressão, ansiedade, dor, inflamação, enxaqueca, êmese ou neuralgia pós-terpética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121874.2A GB0121874D0 (en) | 2001-09-10 | 2001-09-10 | Therapeutic agents |
| PCT/GB2002/004085 WO2003022839A1 (en) | 2001-09-10 | 2002-09-06 | Tetrahydropyran derivatives and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212454A true BR0212454A (pt) | 2004-10-19 |
Family
ID=9921835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212454-8A BR0212454A (pt) | 2001-09-10 | 2002-09-06 | Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7265110B2 (pt) |
| EP (1) | EP1427723B1 (pt) |
| JP (1) | JP2005506329A (pt) |
| KR (1) | KR20040045435A (pt) |
| CN (1) | CN1578778A (pt) |
| AT (1) | ATE328881T1 (pt) |
| BR (1) | BR0212454A (pt) |
| CA (1) | CA2459464A1 (pt) |
| DE (1) | DE60212153T2 (pt) |
| ES (1) | ES2263803T3 (pt) |
| GB (1) | GB0121874D0 (pt) |
| IL (1) | IL160785A0 (pt) |
| MX (1) | MXPA04002295A (pt) |
| NO (1) | NO20041431L (pt) |
| PL (1) | PL368208A1 (pt) |
| RU (1) | RU2004110950A (pt) |
| WO (1) | WO2003022839A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121874D0 (en) | 2001-09-10 | 2001-10-31 | Merck Sharp & Dohme | Therapeutic agents |
| GB0217068D0 (en) * | 2002-07-23 | 2002-08-28 | Merck Sharp & Dohme | Therapeutic agents |
| US7393858B2 (en) * | 2003-03-07 | 2008-07-01 | Merck Sharp & Dohme Ltd. | Tetrahydropyran compounds as tachykinin antagonists |
| WO2019094631A1 (en) * | 2017-11-08 | 2019-05-16 | Washington University | Compounds and methods for treating bacterial infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ332777A (en) * | 1996-06-21 | 2000-06-23 | Merck Sharp & Dohme | 3,6-bi-phenyl substituted spiro-piperidine derivatives |
| CO5150225A1 (es) * | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
| GB0020721D0 (en) * | 2000-08-22 | 2000-10-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB0121874D0 (en) | 2001-09-10 | 2001-10-31 | Merck Sharp & Dohme | Therapeutic agents |
-
2001
- 2001-09-10 GB GBGB0121874.2A patent/GB0121874D0/en not_active Ceased
-
2002
- 2002-09-06 WO PCT/GB2002/004085 patent/WO2003022839A1/en not_active Ceased
- 2002-09-06 US US10/488,842 patent/US7265110B2/en not_active Expired - Fee Related
- 2002-09-06 ES ES02755343T patent/ES2263803T3/es not_active Expired - Lifetime
- 2002-09-06 AT AT02755343T patent/ATE328881T1/de not_active IP Right Cessation
- 2002-09-06 CA CA002459464A patent/CA2459464A1/en not_active Abandoned
- 2002-09-06 BR BR0212454-8A patent/BR0212454A/pt not_active Application Discontinuation
- 2002-09-06 DE DE60212153T patent/DE60212153T2/de not_active Expired - Lifetime
- 2002-09-06 JP JP2003526914A patent/JP2005506329A/ja not_active Ceased
- 2002-09-06 CN CNA028214706A patent/CN1578778A/zh active Pending
- 2002-09-06 IL IL16078502A patent/IL160785A0/xx unknown
- 2002-09-06 EP EP02755343A patent/EP1427723B1/en not_active Expired - Lifetime
- 2002-09-06 MX MXPA04002295A patent/MXPA04002295A/es not_active Application Discontinuation
- 2002-09-06 KR KR10-2004-7003573A patent/KR20040045435A/ko not_active Withdrawn
- 2002-09-06 PL PL02368208A patent/PL368208A1/xx not_active Application Discontinuation
- 2002-09-06 RU RU2004110950/04A patent/RU2004110950A/ru not_active Application Discontinuation
-
2004
- 2004-04-06 NO NO20041431A patent/NO20041431L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1427723B1 (en) | 2006-06-07 |
| PL368208A1 (en) | 2005-03-21 |
| US7265110B2 (en) | 2007-09-04 |
| MXPA04002295A (es) | 2004-06-18 |
| GB0121874D0 (en) | 2001-10-31 |
| ES2263803T3 (es) | 2006-12-16 |
| WO2003022839A1 (en) | 2003-03-20 |
| KR20040045435A (ko) | 2004-06-01 |
| NO20041431L (no) | 2004-06-01 |
| DE60212153T2 (de) | 2007-05-24 |
| CN1578778A (zh) | 2005-02-09 |
| JP2005506329A (ja) | 2005-03-03 |
| DE60212153D1 (de) | 2006-07-20 |
| US20040254184A1 (en) | 2004-12-16 |
| RU2004110950A (ru) | 2005-04-10 |
| EP1427723A1 (en) | 2004-06-16 |
| CA2459464A1 (en) | 2003-03-20 |
| ATE328881T1 (de) | 2006-06-15 |
| IL160785A0 (en) | 2004-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| NO20083114L (no) | Polysykliske indazolderivater som er ERK-inhibitorer | |
| DE60305484D1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| BR0309188A (pt) | Compostos pirazolo como agentes antiinflamatórios e analgésicos | |
| SE0102055D0 (sv) | New Compounds | |
| EA200500882A1 (ru) | N-арилсульфонил-3-аминоалкоксииндолы | |
| NO20052182L (no) | Nye forbindelser | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| NO20053483L (no) | 4-Anilinokinazolinderivater for behandling av unormal cellevekst | |
| ATE406363T1 (de) | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten | |
| NO20050903L (no) | Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser | |
| DE602004017141D1 (de) | Tetrahydropyranverbindungen als tachykininantagonisten | |
| ATE398614T1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
| IL160785A0 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
| MX2024014168A (es) | Antagonistas de at2r y usos de estos | |
| BR0014447A (pt) | Derivados de piperidina como inibidores da reabsorção |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |